Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Member News
![Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma](https://cdn.prod.website-files.com/654294ea0ae50d53f68b59d5/654ab416bb3061f7c92c76fd_Screenshot%202019-03-13%2009_28_12.webp)
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Related or similar articles
![](https://cdn.prod.website-files.com/654294ea0ae50d53f68b59d5/654ab48d6be5286f05c6d171_abcuro%20logo.webp)
March 26, 2019
Abcuro announces pre-clinical data on new immuno-oncology target
First in vivo validation of KLRG1 as a new cancer immunotherapy target
Member News
![](https://cdn.prod.website-files.com/654294ea0ae50d53f68b59d5/654ab28c2a5ef7a0736337ff_Image%20by%20Hans%20Reniers.webp)
December 9, 2021
Bulfinch Leases 40,000 Square Feet to Labshares
BOSTON & NEWTON, Mass.--(BUSINESS WIRE)--The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and Labshares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge..
Labshares News
![](https://cdn.prod.website-files.com/654294ea0ae50d53f68b59d5/654ab2da89c0da52db54bdf0_Covid%2019.webp)
April 28, 2020
Labshares Newton Awards Free Project-Based Lab Space to Three Innovative Diagnostics Companies Conducting COVID-19 Research
Labshares Newton, a shared office and laboratory incubator for emerging biotechnology and life science companies, today announced that it has selected three startup companies developing COVID-19 diagnostics to receive free lab space. The companies...
Labshares News